Why Instil Bio, Inc.’s (TIL) Stock Is Up 6.06%
As of Friday, August 21, Instil Bio, Inc.’s TIL share price has surged by 6.06%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Commentary & Analysis
Why Instil Bio, Inc.’s (TIL) Stock Is Down 5.40%
As of Monday, April 27, Instil Bio, Inc.’s TIL share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Instil Bio, Inc.’s (TIL) Stock Is Down 5.99%
As of Friday, April 24, Instil Bio, Inc.’s TIL share price has dipped by 5.99%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Instil Bio, Inc.’s (TIL) Stock Is Down 5.12%
As of Monday, April 20, Instil Bio, Inc.’s TIL share price has dipped by 5.12%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Instil Bio, Inc.’s (TIL) Stock Is Down 5.43%
As of Thursday, April 16, Instil Bio, Inc.’s TIL share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | TIL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $44.4 | $223.5 | 16% |
|
| Shares Out (Mil) | 6.8 | 53.4 | 17% |
|
| Institutional Ownership | 88.7% | 92.9% | 56% |
|
| Float (Mil) | 3.7 | 40.4 | 9% |
|
| Beta | 1.92 | 0.96 | 90% |
|
| Avg Daily Volume (000s) | 75 | 463 | 33% |
|
| Price Change (52-week) |
(61.8%) | 45.9% | 15% |
|
| Growth | TIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (13.6%) | (10.1%) | 26% |
|
| EPS (5yr) | 25.7% | 15.8% | 76 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.7%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.590) | ($1.170) | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 0 | 0 | na | |
| # Rev Down | 1 | 1 | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (6.9%) | (89.1%) | na | |
| Financials | TIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($30) | ($44) | 20% |
|
| EPS (TTM) | ($4.468) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($24) | ($33) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $87 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $66 | $173 | 18% |
|
| Valuation | TIL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.41 | 2.08 | 8% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TIL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (14.1%) | (47.0%) | 23% |
|
| ROE | (25.3%) | (52.7%) | 21% |
|
| Liabilities to Assets | 45.7% | 29.6% | 37% |
|
| F-Score | 3 | 2 | 18% |
|
Instil Bio, Inc. did not pass any screens on 11/2/2026.
